A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 568 (final count)
- Started
- Nov 21, 2022
- Main results expected
- May 15, 2025
- Fully finished
- Jul 7, 2031
- Results posted
- May 27, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis)
Measured over: From date of first dose to date of treatment discontinuation due to AE, assessed after 50 events had occurred, about 2 years since first patient first visit (FPFV).
Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Primary Analysis)
Measured over: From date of first dose to date of treatment discontinuation due to AE, assessed after 67 events had occurred, about 2.5 years since first patient first visit (FPFV),
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05456191 · record last updated 2026-08-26 · checked 2026-11-09 15:47 UTC